Stifel raises Alnylam Pharmaceuticals stock price target to $495 on strong Vutrisiran sales
PositiveFinancial Markets

Stifel has raised its price target for Alnylam Pharmaceuticals to $495, driven by strong sales of Vutrisiran. This increase reflects confidence in the company's growth and the effectiveness of its products, which is great news for investors and the market. As Vutrisiran continues to perform well, it highlights Alnylam's position in the pharmaceutical industry and its potential for future success.
— Curated by the World Pulse Now AI Editorial System